Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd. was f… Read more
Shanghai Rightongene Biotechnology Co. Ltd. A (688217) - Total Liabilities
Latest total liabilities as of June 2025: CN¥40.95 Million CNY
Based on the latest financial reports, Shanghai Rightongene Biotechnology Co. Ltd. A (688217) has total liabilities worth CN¥40.95 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Rightongene Biotechnology Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Shanghai Rightongene Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Rightongene Biotechnology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Rightongene Biotechnology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Q-Free ASA
PINK:QFREF
|
USA | $557.12 Million |
|
Chengdu Dahongli Machinery Co Ltd
SHE:300865
|
China | CN¥207.01 Million |
|
Biofarm Bucure
RO:BIO
|
Romania | RON85.86 Million |
|
FIT Holding Co Ltd
TW:3712
|
Taiwan | NT$60.33 Billion |
|
Air Asia Co Ltd
TW:2630
|
Taiwan | NT$2.77 Billion |
|
Prime US REIT
OTCGREY:KBSUF
|
USA | $698.18 Million |
|
RocKontrol Technology Group Co Ltd
SHG:688051
|
China | CN¥299.83 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Shanghai Rightongene Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Rightongene Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Rightongene Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Shanghai Rightongene Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥65.06 Million | -14.94% |
| 2023-12-31 | CN¥76.48 Million | -31.98% |
| 2022-12-31 | CN¥112.45 Million | +121.06% |
| 2021-12-31 | CN¥50.87 Million | -16.70% |
| 2020-12-31 | CN¥61.07 Million | +27.64% |
| 2019-12-31 | CN¥47.84 Million | -- |